Combination of CRISPR/Cas9 System and CAR-T Cell Therapy:A New Era for Refractory and Relapsed Hematological Malignancies
作者机构：Bone Marrow Transplantation Centerthe First Affiliated HospitalSchool of MedicineZhejiang UniversityHangzhou 310003China Zhejiang Province Engineering Laboratory for Stem Cell and Immunity TherapyHangzhou 310003China Institute of HematologyZhejiang UniversityHangzhou 310003China Zhejiang Laboratory for Systems&Precision MedicineZhejiang University Medical CenterHangzhou 310003China Liangzhu LaboratoryZhejiang University Medical CenterHangzhou 311121China
出 版 物：《Current Medical Science》 (当代医学科学（英文）)
年 卷 期：2021年第41卷第3期
页 面：420-430页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：the National Natural Science Foundation of China(No.81230014,No.81470341,No.81520108002 and No.81500157) the Key Project of Science and Technology Department of Zhejiang Province(No.2018C03016-2) the Key Research and Development Program of Zhejiang Province(No.2019C03016)
主 题：chimeric antigen receptor T cell treatment clustered regularly interspaced short palindromic repeats(CRISPR)/CRISPR-associated nuclease9 gene editing immunotherapy hematologic malignancy
摘 要：Chimeric antigen receptor T(CAR-T)cell therapy is the novel treatment strategy for hematological malignancies such as acute lymphoblastic leukemia(ALL),lymphoma and multiple ***,treatment-related toxicities such as cytokine release syndrome(CRS)and immune effector cell-associated neurotoxicity syndrome(ICANS)have become significant hurdles to CAR-T *** strategies were established to alter the CAR structure on the genomic level to improve efficacy and reduce ***,the innovative gene-editing technology-clustered regularly interspaced short palindromic repeats(CRISPR)/CRISPR-associated nuclease9(Cas9)system,which particularly exhibits preponderance in knock-in and knockout at specific sites,is widely utilized to manufacture CAR-T *** application of CRISPR/Cas9 to CAR-T cell therapy has shown promising clinical results with minimal *** this review,we summarized the past achievements of CRISPR/Cas9 in CAR-T therapy and focused on the potential CAR-T targets.
维普期刊数据库